Skip to main content

Main menu

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums

User menu

  • My alerts

Search

  • Advanced search
The College of Family Physicians of Canada
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums
  • My alerts
The College of Family Physicians of Canada

Advanced Search

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • RSS feeds
  • Follow cfp Template on Twitter
LetterLetters

Nortriptyline safer than amitriptyline?

Cait O’Sullivan and Cristi Froyman
Canadian Family Physician September 2018, 64 (9) 634-636;
Cait O’Sullivan
Courtenay, BC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cristi Froyman
Kelowna, BC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • eLetters
  • Info & Metrics
  • PDF
Loading

The review of the Canadian Pain Society’s recent consensus statement on chronic neuropathic pain that appeared in the November 2017 issue of Canadian Family Physician reads as follows:

When prescribing TCAs [tricyclic antidepressants], secondary amines (nortriptyline, desipramine) are usually better tolerated in terms of sedation, postural hypotension, and anticholinergic effects when compared with tertiary amines (amitriptyline and imipramine) with comparable analgesic efficacy.1

The reference cited for this statement by the Canadian Pain Society is a review published in 1996.2 We combed through this review and could not find any evidence to substantiate this claim. On the matter of adverse events, it finds that “The two reports with dichotomous data on comparisons of different tricyclics did not show any significant difference.”2

The 2015 Cochrane systematic review of nortriptyline for neuropathic pain reiterates the general view that “nortriptyline is sometimes preferred to amitriptyline because it reputedly has a lower incidence of associated adverse effects.”3 The reviewers subsequently describe the state of adverse event reporting in nortriptyline trials as “inconsistent and fragmented.”3 However, in a contemporary neuropathic pain trial involving randomization to nortriptyline, dry mouth (a classic anticholinergic harm) seems to us remarkably common—affecting almost 60% of participants receiving the drug.4

This leads us to a couple of questions:

  1. If nortriptyline is the principal active metabolite of amitriptyline,3 is it likely that nortriptyline offers a meaningful safety advantage?

  2. Do tricyclic antidepressants even “work”? The 2015 Cochrane systematic review for nortriptyline identified 6 trials enrolling just 310 participants.3 The reviewers write, “The studies were methodologically flawed, largely due to small size, and potentially subject to major bias.”3

Footnotes

  • Competing interests

    None declared

  • Copyright© the College of Family Physicians of Canada

References

  1. 1.↵
    1. Mu A,
    2. Weinberg E,
    3. Moulin DE,
    4. Clarke H
    . Pharmacologic management of chronic neuropathic pain. Review of the Canadian Pain Society consensus statement. Can Fam Physician 2017;63:844-52.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. McQuay HJ,
    2. Tramèr M,
    3. Nye BA,
    4. Carroll D,
    5. Wiffen PJ,
    6. Moore RA
    . A systematic review of antidepressants in neuropathic pain. Pain 1996;68(2–3):217-27.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Derry S,
    2. Wiffen PJ,
    3. Aldington D,
    4. Moore RA
    . Nortriptyline for neuropathic pain in adults. Cochrane Database Syst Rev 2015;(1):CD011209.
  4. 4.↵
    1. Gilron I,
    2. Bailey J,
    3. Tu D,
    4. Holden R,
    5. Jackson A,
    6. Houlden R
    . Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial. Lancet 2009;374(9697):1252-61. Epub 2009 Sep 30.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Canadian Family Physician: 64 (9)
Canadian Family Physician
Vol. 64, Issue 9
1 Sep 2018
  • Table of Contents
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on The College of Family Physicians of Canada.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Nortriptyline safer than amitriptyline?
(Your Name) has sent you a message from The College of Family Physicians of Canada
(Your Name) thought you would like to see the The College of Family Physicians of Canada web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Nortriptyline safer than amitriptyline?
Cait O’Sullivan, Cristi Froyman
Canadian Family Physician Sep 2018, 64 (9) 634-636;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Respond to this article
Share
Nortriptyline safer than amitriptyline?
Cait O’Sullivan, Cristi Froyman
Canadian Family Physician Sep 2018, 64 (9) 634-636;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Footnotes
    • References
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Excellent chronic pain guideline
  • Treating the vaccine hesitant
  • Participation francophone à Forum en médecine familiale
Show more Letters

Similar Articles

Navigate

  • Home
  • Current Issue
  • Archive
  • Collections - English
  • Collections - Française

For Authors

  • Authors and Reviewers
  • Submit a Manuscript
  • Permissions
  • Terms of Use

General Information

  • About CFP
  • About the CFPC
  • Advertisers
  • Careers & Locums
  • Editorial Advisory Board
  • Subscribers

Journal Services

  • Email Alerts
  • Twitter
  • RSS Feeds

Copyright © 2022 by The College of Family Physicians of Canada

Powered by HighWire